

Stomach Cancer Medications

*generic version available

E experimental

Chemotherapy Medications [Learn more >>](#) [More >>](#)

| DRUG | GENERIC NAME | DRUG INDICATION |
|------------------------------|--------------|--|
| Chemotherapy | Multiple | Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here . |

Immunotherapy Medications [Learn more >>](#) [More >>](#)

| DRUG | GENERIC NAME | DRUG INDICATION |
|--------------------------|---------------|---|
| Keytruda | pembrolizumab | Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, stomach cancer, classic Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma and pre- and post-surgery treatment of triple-negative breast cancer. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden. |

| DRUG | GENERIC NAME | DRUG INDICATION |
|------------------------|--------------|--|
| Opdivo | nivolumab | Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, advanced stomach and esophageal cancer, malignant pleural mesothelioma and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations. |

Targeted Therapy Medications [Learn more >>](#) [More >>](#)

| DRUG | GENERIC NAME | DRUG INDICATION |
|---------------------------|------------------------------------|--|
| Cynamza | ramucirumab | Cynamza is a VEGFR2 inhibitor approved for treatment of cancer of the stomach or gastroesophageal junction (where the stomach meets the esophagus), metastatic non-small-cell lung cancer, metastatic colorectal cancer and inoperable or metastatic liver cancer. |
| Enhertu | fam-trastuzumab deruxtecan-nxki | Enhertu is a HER2 antibody combined with a chemotherapy drug. It is approved for previously treated people with inoperable or metastatic HER2-positive breast cancer and for people with locally advanced or metastatic HER2-positive stomach or gastroesophageal junction cancer. |
| Herceptin | trastuzumab | Herceptin is a HER2 inhibitor approved for adjuvant (post-surgery) therapy of early breast cancer and treatment of metastatic breast cancer, stomach cancer and esophageal cancer that overexpresses human epidermal growth factor receptor 2. |
| Rozlytrek | entrectinib | Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer. |
| Vitrakvi | larotrectinib | Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions. |

DRUG [Chemotherapy](#)
GENERIC NAME Multiple

DRUG [Chemotherapy](#)

DRUG INDICATION

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, [click here](#).

DRUG [Keytruda](#)

GENERIC NAME pembrolizumab

DRUG INDICATION

Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, stomach cancer, classic Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma and pre- and post-surgery treatment of triple-negative breast cancer. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden.

DRUG [Opdivo](#)

GENERIC NAME nivolumab

DRUG INDICATION

Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, advanced stomach and esophageal cancer, malignant pleural mesothelioma and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations.

DRUG [Cynamza](#)

GENERIC NAME ramucirumab

DRUG INDICATION

Cynamza is a VEGFR2 inhibitor approved for treatment of cancer of the stomach or gastroesophageal junction (where the stomach meets the esophagus), metastatic non-small-cell lung cancer, metastatic colorectal cancer and inoperable or metastatic liver cancer.

DRUG [Enhertu](#)

GENERIC NAME fam-trastuzumab deruxtecan-nxki

DRUG INDICATION

Enhertu is a HER2 antibody combined with a chemotherapy drug. It is approved for previously treated people with inoperable or metastatic HER2-positive breast cancer and for people with locally advanced or metastatic HER2-positive stomach or gastroesophageal junction cancer.

DRUG [Herceptin](#)

GENERIC NAME trastuzumab

DRUG INDICATION

Herceptin is a HER2 inhibitor approved for adjuvant (post-surgery) therapy of early breast cancer and treatment of metastatic breast cancer, stomach cancer and esophageal cancer that overexpresses human epidermal growth factor receptor 2.

DRUG Rozlytrek**GENERIC NAME** entrectinib**DRUG INDICATION**

Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.

DRUG Vitrakvi**GENERIC NAME** larotrectinib**DRUG INDICATION**

Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.

© 2026 Smart + Strong All Rights Reserved.

http://beta.docker.cancerhealth.com/drug_charts/stomach-cancer-medications-drugs